Last reviewed · How we verify

NCT06888128: STARLIGHT

State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma

Recruiting now Phase 2 Last updated 22 January 2026
What this trial tests

Phase 2 trial testing Psilocybin 15mg in PTSD in 15 participants. Currently enrolling.

Timeline
30 January 2025
Primary endpoint
15 December 2026
15 December 2026

Quick facts

Lead sponsorBaylor College of Medicine
PhasePhase 2
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment15
Start date30 January 2025
Primary completion15 December 2026
Estimated completion15 December 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Baylor College of Medicine

Who can join

Adults 21 to 64, any sex, with PTSD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The principal investigator for this study plans to build upon the psilocybin-assisted therapy intervention used in prior completed trials to conduct an open-label trial of two psilocybin administration sessions combined with psychotherapy to investigate the safety, tolerability, and clinical efficacy of psilocybin-assisted therapy for the treatment of PTSD in US Veterans.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for PTSD

Currently open trials in the same condition.

Other Baylor College of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06888128.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing